



Mayo Translational Polycystic Kidney Disease (PKD) Center

2010 publications by center faculty

1. Wang X, Ward CJ, Harris PC, Torres VE. Cyclic nucleotide signaling in polycystic kidney disease. *Kidney International*. 2010;77:129.
2. Waanders E, Venselaar H, te Morsche RH, deKoning DB, Kamath PS, Torres VE, Somlo S, Drenth JP. Secondary and tertiary structure modeling reveals effects of novel mutations in polycystic liver disease genes PRKCSH and SEC63. *Clinical Genetics*. 2010;78:47.
3. Torres VE. Treatment strategies and clinical trial design in ADPKD. *Advances in Chronic Kidney Disease*. 2010;17:190.
4. Dambreville S, Chapman AB, Torres VE, King BF, Wallin AK, Frakes DH, Yoganathan AP, Wijayawardana SR, Easley K, Bae K, Brummer ME. Renal arterial blood flow measurement by breath-held MRI: Accuracy in phantom scans and reproducibility in healthy subjects. *Magnetic Resonance in Medicine*. 2010;63:940.
5. Torres VE, Boletta A, Chapman A, Gattone V, Pei Y, Qian Q, Wallace DP, Weimbs T, Wuthrich RP. Prospects for mTOR inhibitor use in patients with polycystic kidney disease and hamartomatous diseases. *Clinical Journal of the American Society of Nephrology*. 2010;5:1312.
6. Hogan MC, Masyuk T, Page LJ, Kubly VJ, Bergstralh EJ, Li X, Kim B, King BF, Glockner J, Holmes DR 3rd, Rossetti S, Harris PC, LaRusso NF, Torres VE. Randomized clinical trial of long acting somatostatin therapy in autosomal dominant polycystic kidney and liver disease. *Journal of the American Society of Nephrology*. 2010;21:1052.
7. Liu M, Shi S, Senthilnathan S, Yu J, Wu E, Bergmann C, Zerres K, Bogdanova N, Coto E, Deltas C, Pierides A, Demetriou K, Devuyst O, Gitomer B, Laakso M, Lumiaho A, Lamnissou K, Magistroni R, Parfrey P, Breuning M, Peters DJ, Torra R, Winearls CG, Torres VE, Harris PC, Paterson AD, Pei Y. Genetic variation of DKK3 may modify renal disease severity in ADPKD. *Journal of the American Society of Nephrology*. 2010;21:1510.
8. Vujic M, Heyer CM, Ars E, Hopp K, Markoff A, Orndal C, Rudenhed B, Nasr SH, Torres VE, Torra R, Bogdanova N, Harris PC. Incompletely penetrant PKD1 alleles mimic the renal manifestations of ARPKD. *Journal of the American Society of Nephrology*. 2010;21:1097.
9. Blazer-Yost BL, Haydon J, Eggleston-Gulyas T, Chen JH, Wang X, Gattone V, Torres VE. Pioglitazone attenuates cystic burden in the PCK rodent model of polycystic kidney disease. *PPAR Research*. 2010;2010:274376.
10. Irazabal MV, Huston J 3rd, Kubly V, Rossetti S, Sundsbak JL, Hogan MC, Harris PC, Brown RD Jr, Torres VE. Extended follow-up of unruptured intracranial aneurysms detected by presymptomatic screening in patients with autosomal dominant polycystic kidney disease. *Clinical Journal of the American Society of Nephrology*. 2011;6:1274.
11. Drenth JP, Chrispijn M, Nagorney DM, Kamath PS, Torres VE. Medical and surgical treatment options for polycystic liver disease. *Hepatology*. 2010;52:2223.

12. Kurbegovic A, Gote O, Couillard M, Ward CJ, Harris PC, Trudel M. PKD1 transgenic mice: Adult model of polycystic kidney disease with extrarenal and renal phenotypes. *Human Molecular Genetics*. 2010;19:1174.
13. Canaud G, Knebelmann B, Harris PC, Vrtovsnik F, Correas JM, Pallet N, Heyer CM, Letavernier E, Bienaime F, Thervet E, Martinez F, Terzi F, Legendre C. Therapeutic mTOR inhibition in autosomal dominant polycystic kidney disease: What is the appropriate serum level? *American Journal of Transplantation*. 2010;10:1701.
14. Mason SB, Liang Y, Sinderson RM, Miller CA, Eggleston-Gulyas T, Crisler-Roberts R, Harris PC, Gattone VH 2nd. Disease stage characterization of hepatorenal fibrocystic pathology in the PCK rat model of ARPKD. *Anatomical Record*. 2010;293:1279.
15. Stroope A, Radtke B, Huang B, Masyuk T, Torres V, Ritman E, LaRusso N. Hepato-renal pathology in *pkd2ws25/-* mice, an animal model of autosomal dominant polycystic kidney disease. *The American Journal of Pathology*. 2010;176:1282.
16. Gradilone SA, Masyuk TV, Huang BQ, Banales JM, Lehmann GL, Radtke BN, Stroope A, Masyuk AI, Splinter PL, LaRusso NF. Activation of Trpv4 reduces the hyperproliferative phenotype of cystic cholangiocytes from an animal model of ARPKD. *Gastroenterology*. 2010;139:304.
17. Li Y, Wei Q, Zhang Y, Ling K, Hu J. The small GTPases ARL-13 and ARL-3 coordinate intraflagellar transport and ciliogenesis. *The Journal of Cell Biology*. 2010;189:1039.
18. Otto EA, Hurd TW, Airik R, Chaki M, Zhou W, Stoetzel C, Patil SB, Levy S, Ghosh AK, Murga-Zamalloa, CA, van Reeuwijk J, Letteboer SJF, Sang L, Giles RH, Liu Q, Coene KLM, Estrada-Cuzcano A, Collin RWJ, McLaughlin HM, Held S, Kananuki JM, Ramaswami G, Conte J, Lopez I, Washburn J, MacDonald J, Hu J, Yamashita Y, Maher ER, Guay-Woodford LM, Neumann HPH, Obermüller N, Koeneke RK, Bergmann C, Bei X, Lewis RA, Katsanis N, Lopes V, Williams DS, Lyons RH, Dang CV, Brito DA, Dias MB, Zhang X, Cavalcoli JD, Nürnberg G, Nürnberg P, Pierce EA, Jackson PK, Antignac C, Saunier S, Roepman R, Dollfus H, Khanna H, Hildebrandt F. Candidate exome capture identifies mutation of *SDCCAG8* as the cause of a retinal-renal ciliopathy. *Nature Genetics*. 2010;42:840.